Botox 200 unit vials
Ended Awarded
- Contract number
- SPE2DB26FAZBB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $67,919
Award facts
- Contract value 100% obligated
- $67,919.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $67,919.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botox 200 unit vials. The award, issued on October 22, 2025, with an ultimate completion date of November 13, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group's established supplier status within the federal pharmaceutical supply chain positions it as a critical vendor for DoD medical operations. The contractor maintains a robust product portfolio spanning branded and generic pharmaceuticals, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V contract structure, with a 30-month base period and three 30-month option periods extending through December 31, 2036, enables DLA to issue firm fixed-price delivery orders for recurring medical supply needs across the global military healthcare system, with DMS Pharmaceutical Group's demonstrated performance on numerous prior delivery orders affirming its capability to fulfill specialized pharmaceutical requirements.
Quick answers
Who was awarded contract SPE2DB26FAZBB?
SPE2DB26FAZBB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DB26FAZBB worth?
The government has obligated $67,919 on SPE2DB26FAZBB.
Is contract SPE2DB26FAZBB an order under another contract?
Yes. SPE2DB26FAZBB is a delivery order under SPE2DB24D9222, an indefinite delivery contract.
Was contract SPE2DB26FAZBB competed?
The extent of competition for SPE2DB26FAZBB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award